Biofrontera Inc (BFRI)

Currency in USD
0.5300
-0.0400(-7.02%)
Closed·
0.6100+0.0800(+15.09%)
·
Advertisement
Unusual Post-Market activity
Trading near 52-week Low
BFRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.53000.5882
52 wk Range
0.53001.6600
Key Statistics
Prev. Close
0.53
Open
0.5697
Day's Range
0.53-0.5882
52 wk Range
0.53-1.66
Volume
196.11K
Average Volume (3m)
430.87K
1-Year Change
-28.359%
Book Value / Share
-0.016
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BFRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.0000
Upside
+466.04%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Biofrontera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.0000
(+466.04% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
StoneX
Buy3.00+466.04%-Maintain15/09/2026
Benchmark
Buy3.00+466.04%-Downgrade19/05/2026

Biofrontera Inc Earnings Call Summary for Q3/2026

  • Q3 revenue rose 30% YoY to $9.1M driven by Ameluz volume growth and pricing, but EPS loss of $0.42 missed estimates by 190%.
  • Gross margin improved to 74.4% from 70.7%; FDA approved Ameluz for superficial basal cell carcinoma, creating second U.S. indication.
  • Stock fell 6% to $0.87 as company warned of substantial going-concern doubt with only $3.2M cash and Nasdaq equity deficiency.
  • Q4 expected to be strongest quarter with 80% gross margin; full sBCC commercial launch planned for Q1 2027 after FDA marketing review.
  • Company pursuing $1M milestone payment in Dec 2026 and working credit line; lamp remediation to complete by Q2 2027.
Last Updated: 13/11/2026, 15:38
Read Full Transcript

Earnings

Latest Release
13/11/2026
EPS / Forecast
-0.42 / -0.15
Revenue / Forecast
9.07M / 9M
EPS Revisions
Last 90 days

Compare BFRI to Peers and Sector

Metrics to compare
BFRI
Peers
Sector
Relationship
P/E Ratio
−1.5x−4.7x−0.2x
PEG Ratio
−0.02−0.030.00
Price/Book
−39.1x1.2x2.6x
Price / LTM Sales
0.2x1.7x2.6x
Upside (Analyst Target)
-136.2%76.9%
Fair Value Upside
Unlock6.3%14.9%Unlock

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Employees
89

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
361.97K2.44%217.11K
Other Institutional Investors
6.51M43.81%3.90M
Public Companies & Retail Investors
7.98M53.75%4.79M
Total
14.85M100.00%8.91M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Aigh Capital Management, LLC10.08%1,496,583898
Rosalind Master Fund L.P.8.59%1,275,609765

People Also Watch

0.2300
CDT
-13.89%
2.335
ALEC
+1.52%
0.3300
BYSI
-24.49%
4.340
CLRO
-21.09%
0.3753
BZFD
+2.79%

FAQ

What Is the Biofrontera (NASDAQ: BFRI) Share Price Today?

The Biofrontera stock price today is 0.5300 USD.

What Stock Exchange Does Biofrontera (BFRI) Trade On?

Biofrontera is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Biofrontera?

The stock symbol (also called a 'ticker') for Biofrontera is "BFRI."

What Is the Current Biofrontera Market Capitalisation?

As of today, Biofrontera (NASDAQ: BFRI) market cap is 10.2300M USD.

What Is Biofrontera's (BFRI) Earnings Per Share (TTM)?

The Biofrontera EPS is currently -0.48 (Trailing Twelve Months).

When Is the Next Biofrontera Earnings Date?

Biofrontera's next earnings report will be released on 19/03/2027.

Is BFRI a Buy or Sell From a Technical Analyst Perspective?

Based on today's Biofrontera moving averages and other technical indicators, the daily buy/sell signal for BFRI stock is Strong Sell.

How Many Times Has Biofrontera Stock Split?

Biofrontera has split 1 times. (See the BFRI stock split history page for full effective split date and price information.)

How Many Employees Does Biofrontera Have?

Biofrontera has 89 employees, based on their latest Companies House report.

What is the current trading status of Biofrontera (NASDAQ: BFRI)?

As of 21/11/2026, Biofrontera (BFRI) is trading at a share price of 0.5300 USD, with a previous close of 0.5300 USD. The stock has fluctuated within a day range of 0.5300 USD to 0.5882 USD, while its 52-week range spans from 0.5300 USD to 1.6600 USD.

What Is Biofrontera (BFRI) Price Target According to Analysts?

The average 12-month price target for Biofrontera is 3.0000 USD, with a high estimate of 3 USD and a low estimate of 3 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +466.04% Upside potential.

What Is the BFRI After Hours Price?

BFRI's last after hours stock price is 0.6100 USD, the stock has decreased by 0.0800, or 15.0900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.